Afinitor

Afinitor (everolimus) is indicated for the treatment of advanced renal cell carcinoma that has progressed during or after VEGF-targeted therapy.

Everolimus inhibits mTOR (mammalian target of rapamycin), a serine/threonine kinase that regulates a variety of key cellular processes and is upregulated in several types of cancer.

In a Phase III trial in 416 patients with metastatic renal cell carcinoma whose disease had progressed despite VEGF-targeted treatment with sunitinib and/or sorafenib, the median duration of progression-free survival was 4.9 months on everolimus compared with 1.9 months on placebo.

Afinitor is not recommended for patients with severe hepatic impairment.

View Afinitor drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Stressed male GP with hand on head
Pseudoephedrine written

Pseudoephedrine prescribing information to highlight rare brain disorder risk

Safety information for pseudoephedrine products will...

New generics tracker

New generics - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest generic drugs...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...